Cancer Letters, Journal Year: 2024, Volume and Issue: 604, P. 217222 - 217222
Published: Sept. 7, 2024
Language: Английский
Cancer Letters, Journal Year: 2024, Volume and Issue: 603, P. 217213 - 217213
Published: Sept. 6, 2024
Language: Английский
Citations
7
Cancer Letters, Journal Year: 2024, Volume and Issue: 598, P. 217117 - 217117
Published: July 15, 2024
Cancer cells rewire metabolism to sculpt the immune tumor microenvironment (TME) and propel advancement, which intricately tied post-translational modifications. Histone lactylation has emerged as a novel player in modulating protein functions, whereas little is known about its pathological role pancreatic ductal adenocarcinoma (PDAC) progression. Employing multi-omics approach encompassing bulk single-cell RNA sequencing, metabolomics, ATAC-seq, CUT&Tag methodologies, we unveiled potential of histone prognostic prediction, patient stratification TME characterization. Notably, "LDHA-H4K12la-immuno-genes" axis introduced node into regulatory framework "metabolism-epigenetics-immunity," shedding new light on landscape PDAC Furthermore, heightened interplay between cancer counterparts via Nectin-2 liver metastasis with elevated HLS unraveled positive feedback loop driving evasion. Simultaneously, exhibited altered autonomous functionality across metastatic cascade. Consequently, exploration innovative combination strategies targeting metabolism-epigenetics-immunity holds promise curbing distant improving survival prospects for individuals grappling challenges PDAC.
Language: Английский
Citations
6
Cancer Letters, Journal Year: 2024, Volume and Issue: 598, P. 217097 - 217097
Published: July 2, 2024
Language: Английский
Citations
4
Andrology, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 25, 2025
Despite its rarity, testicular germ cell tumor (TGCT) is commonly diagnosed in young males aged 20-40. In recent years, the global prevalence of TGCT has gradually increased, with 12-30% patients experiencing relapse and metastasis. However, there are currently no reliable biomarkers for accurately predicting prognosis patients. Therefore, identifying novel risk stratification an immediate priority. Using samples from multiple centers, we identified a prognostic biomarker (SMAD family member 6 [SMAD6]) through differential expression analysis, Cox regression, survival analysis. Immunohistochemistry (IHC) was then employed to evaluate SMAD6 levels normal tissues samples. Finally, examined relationship between biological characteristics, mutation landscape, immune infiltration, response immunotherapy. Our study as factor prognosis. IHC revealed significant tissues. Functional enrichment analysis indicated that may contribute activation progression-related pathways suppression immune-related pathways. Additionally, high correlated reduced CD8+ T while low benefited more This highlights potential be useful immunotherapy prediction, offering promising target personalized medicine strategies.
Language: Английский
Citations
0
Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16
Published: March 7, 2025
Pancreatic cancer is renowned for its aggressive nature and dismal prognosis, with the majority of patients diagnosed at an advanced stage. The prognosis pancreatic can be improved by early diagnosis effective treatment. Circulating cell-free DNA (cfDNA) has emerged as a promising biomarker monitoring cancer. This research presents review circulating essential role in immunotherapy detection methods cfDNA, potential diagnostic biomarker, latest progress cfDNA-based are discussed. findings suggest that cfDNA plays vital personalised treatment cancer, holding great promise improving patient outcomes.
Language: Английский
Citations
0
MedComm, Journal Year: 2025, Volume and Issue: 6(4)
Published: April 1, 2025
ABSTRACT Pancreatic cancer (PC) is a highly lethal malignancy, with pancreatic ductal adenocarcinoma (PDAC) being the most common and aggressive subtype, characterized by late diagnosis, progression, resistance to conventional therapies. Despite advances in understanding its pathogenesis, including identification of genetic mutations (e.g., KRAS, TP53, CDKN2A, SMAD4) dysregulated signaling pathways KRAS–MAPK, PI3K–AKT, TGF‐β pathways), effective therapeutic strategies remain limited. Current treatment modalities chemotherapy, targeted therapy, immunotherapy, radiotherapy, emerging therapies such as antibody–drug conjugates (ADCs), chimeric antigen receptor T (CAR‐T) cells, oncolytic viruses (OVs), vaccines, bispecific antibodies (BsAbs), face significant challenges. This review comprehensively summarizes these approaches, emphasizing their mechanisms, limitations, potential solutions, overcome bottlenecks. By integrating recent advancements outlining critical challenges, this aims provide insights into future directions guide development more for PC, specific focus on PDAC. Our work underscores urgency addressing unmet needs PDAC therapy highlights promising areas innovation field.
Language: Английский
Citations
0
Cancer Letters, Journal Year: 2025, Volume and Issue: unknown, P. 217689 - 217689
Published: April 1, 2025
Language: Английский
Citations
0
Cancers, Journal Year: 2025, Volume and Issue: 17(7), P. 1226 - 1226
Published: April 4, 2025
Pancreatic Ductal Adenocarcinoma (PDAC) belongs to the types of cancer with highest lethality. It is also remarkably chemoresistant few available cytotoxic therapeutic options. PDAC characterized by limited mutational heterogeneity known driver genes, KRAS, CDKN2A, TP53, and SMAD4, observed in both early-stage advanced tumors. In this review, we summarize two proposed models genetic evolution pancreatic cancer. The gradual or stepwise accumulated mutations model has been widely studied. On contrary, less evidence exists on more recent simultaneous model, according which rapid tumor driven concurrent accumulation alterations. models, oncogenic KRAS are main initiating event. Here, analyze emerging topic allelic imbalances how it arises during evolution, as often detected metastatic PDAC. We affects biology, metastasis, response therapy. To extent, highlight necessity include studies frequencies design future strategies against
Language: Английский
Citations
0
Seminars in Oncology, Journal Year: 2025, Volume and Issue: 52(2), P. 152338 - 152338
Published: April 1, 2025
Language: Английский
Citations
0
Small Structures, Journal Year: 2025, Volume and Issue: unknown
Published: May 6, 2025
To address the challenges of limited drug accumulation and penetration in pancreatic ductal adenocarcinoma (PDAC), a cascade ultrasonic cavitation strategy designed to enhance delivery by sequentially overcoming biological barriers is developed. This approach employs macrophage membrane‐modified microbubble–nanoparticle hybrid (MMB@TFHPD) capable cavitation. MMB@TFHPD consists microbubble coating (MMB) mesoporous silica core (TFHPD), coloaded with doxorubicin perfluoropentane. Following intravenous administration, accumulates near tumor endothelial cells via ligand–receptor interaction. Low‐intensity ultrasound (first US) then applied induce primary cavitation, disrupting blood‐tumor barrier enhancing TFHPD NPs accumulate within periphery. Upon exposure acidic microenvironment (TME), surface tannic acid–iron complexes (TA/Fe 3+ ) degrade, exposing structure. High‐intensity US (second subsequently applied, triggering liquid‐to‐gas phase transition PFP microbubbles destruction, which induces extracellular matrix collapse, rapid release, deep into parenchyma. process results potent antitumor effects PDAC therapy. In summary, this study introduces promising overcome key for other solid tumors.
Language: Английский
Citations
0